CVS Health Corporation $CVS Shares Acquired by RFG Advisory LLC

RFG Advisory LLC grew its holdings in CVS Health Corporation (NYSE:CVS) by 315.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 21,998 shares of the pharmacy operator’s stock after buying an additional 16,702 shares during the period. RFG Advisory LLC’s holdings in CVS Health were worth $1,746,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. National Pension Service increased its holdings in shares of CVS Health by 3.1% in the 3rd quarter. National Pension Service now owns 3,999,622 shares of the pharmacy operator’s stock valued at $301,532,000 after acquiring an additional 119,189 shares during the last quarter. Kingsview Wealth Management LLC grew its position in shares of CVS Health by 316.2% during the third quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock worth $7,873,000 after acquiring an additional 79,340 shares during the last quarter. AE Wealth Management LLC grew its stake in shares of CVS Health by 6.2% in the 3rd quarter. AE Wealth Management LLC now owns 257,204 shares of the pharmacy operator’s stock valued at $19,391,000 after purchasing an additional 14,983 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of CVS Health by 11.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 225,116 shares of the pharmacy operator’s stock valued at $16,971,000 after purchasing an additional 22,653 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its stake in shares of CVS Health by 186.6% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 396,368 shares of the pharmacy operator’s stock valued at $30,568,000 after purchasing an additional 258,050 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Trading Up 0.5%

CVS stock opened at $87.34 on Friday. The company has a market cap of $111.93 billion, a price-to-earnings ratio of 38.47, a PEG ratio of 0.91 and a beta of 0.60. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The business has a fifty day simple moving average of $76.86 and a 200-day simple moving average of $78.03. CVS Health Corporation has a 52 week low of $58.35 and a 52 week high of $88.63.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, equities research analysts expect that CVS Health Corporation will post 7.14 EPS for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were issued a $0.665 dividend. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 annualized dividend and a dividend yield of 3.0%. CVS Health’s dividend payout ratio (DPR) is 192.75%.

Analysts Set New Price Targets

A number of research firms recently weighed in on CVS. Piper Sandler decreased their price target on CVS Health from $101.00 to $99.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 31st. UBS Group lifted their price target on CVS Health from $97.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday. Wolfe Research decreased their price target on CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a research note on Monday, March 2nd. Barclays lifted their price target on CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, Truist Financial lifted their price objective on CVS Health from $98.00 to $102.00 and gave the stock a “buy” rating in a report on Thursday. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $95.88.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Q1 earnings and guidance beat — CVS reported Q1 adjusted EPS of $2.57 and revenue of $100.4B, topped estimates and raised full‑year 2026 adjusted EPS guidance to $7.30–$7.50, driven by insurance margin improvement and reserve benefits. This is the primary catalyst lifting the stock. CVS Health raises 2026 forecast after improving medical cost controls
• Positive Sentiment: Broker optimism and price-target increases — Multiple firms (Truist, UBS, DA Davidson, Deutsche Bank and others) bumped price targets and reiterated/maintained buy ratings, signaling analyst confidence that improved insurance performance and guidance justify higher valuation. Benzinga Deutsche Bank adjusts CVS Health price target DA Davidson raises price target
• Positive Sentiment: Improving insurance (Aetna) profitability — Management cited lower medical benefit ratios and better cost controls in government plans; Aetna’s turnaround is driving margin expansion and was highlighted repeatedly on the call. CVS blows past estimates, hikes outlook as insurance business outperforms
• Positive Sentiment: Retail operations showing strength — Increased prescription volume and retail pharmacy trends supported revenue growth and margin expansion, reinforcing the diversified earnings base. CVS’s increased prescription volume leads to solid Q1
• Neutral Sentiment: Strategic initiatives (biosimilars, AI, community programs) — CVS announced wider biosimilar formulary adoption and AI-driven affordability programs that could lower costs and boost long‑term margins, but near‑term impact is gradual. CVS Health Bets On Biosimilars And AI To Support Affordable Care
• Neutral Sentiment: Economic/PR pieces — Reports on CVS’s large national economic footprint and community programs support brand and regulatory goodwill but have limited immediate share‑price impact. CVS Health’s Annual Impact in Connecticut
• Negative Sentiment: Valuation and structural PBM concerns — Some analysts and industry pieces warn that a temporary insurance profitability tailwind may mask longer‑term margin pressure in the PBM/business transformation, suggesting upside may be capped until sustainable improvement is proven. How CVS Health’s Transformation Is Facing A Hard Valuation Floor

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.